Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for SEVELAMER CARBONATE
- A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients
- A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505 to Treat Hyperphosphatemia in Hemodialysis Patients
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat
- A Long-Term Study to Evaluate the Ability of Tenapanor Alone or in Combination With Sevelamer to Treat to Goal Serum Phosphorus in Patients With End-Stage Kidney Disease on Dialysis
- Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
- PA21 Safety and Efficacy in Adult Chinese Subjects
- The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
- Different Effects of Non-calcium Phosphate Binders on Serum Calcium
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
- DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
- Hyperphosphatemia in Children With Chronic Kidney Disease
- A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
- A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
- A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
- An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients
- Optimal Anemia Treatment in End Stage Renal Disease (ERSD)
- Phophate Lowering Trial
- Sevelamer in Proteinuric CKD
- Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
- Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
- Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark Study
- An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease
- Sevelamer for Reducing Endotoxemia and Immune Activation
- The Effects of Sevelamer Carbonate on Diabetic Nephropathy
- A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
- Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients
- A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
- Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease
- Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4
- The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
- FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
- Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
- Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease
- FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
- Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy
- The Pharmacokinetics of Rocaltrol When Administered Alone or in Combination With Fosrenol or Renvela in Healthy Volunteers
- Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
- Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis
- A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
- Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
- A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD
- An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis
- Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients
- Regulation of Bone Formation in Renal Osteodystrophy
- Efficacy of Phosphate Binding in Healthy Volunteers: Chewed Versus Crushed Lanthanum Carbonate
- Head to Head Study Against Sevelamer Hydrochloride
- Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate
- Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate
- Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis
- Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer HCl Tablets in Haemodialysis Patients
- Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease
Clinical trials list
click for details